PCSK9 Biology, PCSK9 Inhibitors, Cardiovascular Outcomes, and Pleiotropic Effects: Scoping Review with ☸️SAIMSARA.

Name: SAIMSARA Evidence Object vascular::PCSK9_BIOLOGY_INHIBITORS_PM
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsarac25dcb0d

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

PCSK9 Biology, PCSK9 Inhibitors, Cardiovascular Outcomes, and Pleiotropic Effects: Scoping Review with ☸️SAIMSARA.

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsarac25dcb0d

Editorial note

• Last update: 2026-06-06 12:14:00

What is this paper about

PCSK9 is no longer just an LDL-receptor story: this review maps 642 references on its role across lipid lowering, cardiovascular outcomes, inflammation, thrombosis, metabolism, kidney disease, neurobiology, pregnancy, and cancer immunity. The full read shows where PCSK9 inhibition is already clinically strong, where pleiotropic effects may open new therapeutic fields, and where safety or access barriers still limit translation.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Generated with SAIMSARA v5.0

Video summary generated from this ☸️SAIMSARA evidence map. Full reference-linked paper and evidence JSON are available after purchase.

Abstract: To synthesize current evidence regarding PCSK9. The review uses 642 references and builds its evidence map from 3450 original studies with 1149089216 total participants/sample observations (topic-deduplicated ΣN). The mapped evidence supports PCSK9 as a systems-level regulator whose clinical relevance extends well beyond LDL-receptor degradation, with the most robust and recurrent signal being substantial LDL-C lowering (approximately 50–65%) and reduced cardiovascular events across monoclonal antibody, siRNA, and emerging oral and gene-editing modalities. Recurrent LDLR-independent signals in inflammation, thrombosis, and tumor immunity suggest pleiotropic actions that may broaden therapeutic relevance but also introduce context-specific uncertainties in sepsis, pregnancy, neurobiology, and tissue homeostasis. Practically, these findings indicate that PCSK9 inhibition is most informative when interpreted within cardiovascular, metabolic, and renal phenotypes, while real-world uptake remains constrained by access and adherence barriers. Future research should prioritize prospective trials that disentangle LDL-C-mediated from pleiotropic effects and establish population-specific safety in domains where current evidence remains heterogeneous.

Keywords: PCSK9; LDL receptor; Atherosclerosis; Hypercholesterolemia; PCSK9 inhibitors; Inflammation; Cancer immunotherapy; Hepatocellular carcinoma; PI3K/AKT signaling; Cardiovascular disease

Review Stats

Final search date and database lock: 2026-05-28 23:02:54 CEST
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 7229
Downloaded Abstracts/Papers: 7229
Included original and non-original Abstracts/Papers (all): 4772
Included original Abstracts/Papers (Vote counting by direction of effect): 3450
Reference Index (links used in paper): 642
Total participants/sample observations (topic deduplicated ΣN): 1149089216

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (642)

[1] Oral PCSK9 Inhibitors. — https://doi.org/10.1007/s11883-024-01199-2
[2] PCSK9-directed therapies: an update. — https://doi.org/10.1097/mol.0000000000000919
[3] S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. — https://doi.org/10.1016/j.celrep.2022.111194
[4] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. — https://doi.org/10.1038/s41392-023-01690-3
[5] PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages. — https://doi.org/10.1186/s13046-022-02477-0
[6] PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives. — https://doi.org/10.33963/kp.a2023.0030
[7] PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor. — https://doi.org/10.1038/s41467-024-46336-2
[8] Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G. — https://doi.org/10.1172/jci.insight.141193

Unlock the full paper to view the complete Reference Index.